Glaxosmithkline has struck a £1.4billion deal to develop new cancer drugs with a US rival.

The move bolsters the British pharma giant’s pipeline of medicines at a time when boss Emma Walmsley is seeking to reassure investors.

It will pay £443million upfront to Boston-based Iteos Therapeutics, which could then get another £1billion if the deal leads to clinical and commercial breakthroughs.

Glaxosmithkline's deal with Boston-based Iteos Therapeutics bolsters the UK firm's pipeline of medicines at a time when boss Emma Walmsley (pictured) is seeking to reassure investors

Glaxosmithkline's deal with Boston-based Iteos Therapeutics bolsters the UK firm's pipeline of medicines at a time when boss Emma Walmsley (pictured) is seeking to reassure investors

Glaxosmithkline’s deal with Boston-based Iteos Therapeutics bolsters the UK firm’s pipeline of medicines at a time when boss Emma Walmsley (pictured) is seeking to reassure investors

It comes as Walmsley, 52, is trying to convince investors that she is the right person to lead the pharmaceutical and vaccines-focused company after the consumer business is spun off next summer.

She faces potential disruption from feared activist Elliott Management, which took a ‘multi-billion-pound’ stake last month. 

The chief executive is due to set out her long-term plans at a capital markets day on June 23 that is now seen as a crucial test.

There, she will also seek to boost investor confidence in the pipeline of new drugs – and its potential to create future ‘blockbusters’ that generate more than $1billion in annual revenue.

The Iteos deal is to develop EOS-448, an experimental treatment that could be given to patients with certain types of cancer to ‘switch off’ a tumour’s ability to evade the body’s immune system.

EOS-448 is in early trials using patients with advanced solid tumours. Glaxo and Iteos plan to start combination studies of EOS-448 with Glaxo cancer drug Dostarlimab.

Dr Hal Barron, Glaxo science chief, said the trials could prove critical as fewer than 30 per cent of patients respond to similar drugs.

He added: ‘We believe that [these] combinations could become transformative for many patients.’

#fiveDealsWidget .dealItemTitle#mobile {display:none} #fiveDealsWidget {display:block; float:left; clear:both; max-width:636px; margin:0; padding:0; line-height:120%; font-size:12px} #fiveDealsWidget div, #fiveDealsWidget a {margin:0; padding:0; line-height:120%; text-decoration: none; font-family:Arial, Helvetica ,sans-serif} #fiveDealsWidget .widgetTitleBox {display:block; float:left; width:100%; background-color:#af1e1e; } #fiveDealsWidget .widgetTitle {color:#fff; text-transform: uppercase; font-size:18px; font-weight:bold; margin:6px 10px 4px 10px; } #fiveDealsWidget a.dealItem {float:left; display:block; width:124px; margin-right:4px; margin-top:5px; background-color: #e3e3e3; min-height:200px;} #fiveDealsWidget a.dealItem#last {margin-right:0} #fiveDealsWidget .dealItemTitle {display:block; margin:10px 5px; color:#000; font-weight:bold} #fiveDealsWidget .dealItemImage, #fiveDealsWidget .dealItemImage img {float:left; display:block; margin:0; padding:0} #fiveDealsWidget .dealItemImage {border:1px solid #ccc} #fiveDealsWidget .dealItemImage img {width:100%; height:auto} #fiveDealsWidget .dealItemdesc {float:left; display:block; color:#004db3; font-weight:bold; margin:5px;} #fiveDealsWidget .dealItemRate {float:left; display:block; color:#000; margin:5px} #fiveDealsWidget .footerText a:hover{text-decoration: underline;} #fiveDealsWidget .footerSmall{font-size:10px; padding-top:10px;} @media (max-width: 635px) { #fiveDealsWidget a.dealItem {width:19%; margin-right:1%} #fiveDealsWidget a.dealItem#last {width:20%} } @media (max-width: 560px) { #fiveDealsWidget #desktop {display:none;} #fiveDealsWidget #mobile {display:block!important} #fiveDealsWidget a.dealItem {background-color: #fff; height:auto; min-height:auto} #fiveDealsWidget a.dealItem {border-bottom:1px solid #ececec; margin-bottom:5px; padding-bottom:10px} #fiveDealsWidget a.dealItem#last {border-bottom:0px solid #ececec; margin-bottom:5px; padding-bottom:0px} #fiveDealsWidget a.dealItem, #fiveDealsWidget a.dealItem#last {width:100%} #fiveDealsWidget .dealItemContent, #fiveDealsWidget .dealItemImage {float:left; display:inline-block} #fiveDealsWidget .dealItemImage {width:35%; margin-right:1%} #fiveDealsWidget .dealItemContent {width:63%} #fiveDealsWidget .dealItemTitle {margin: 0px 5px 5px; font-size:16px} #fiveDealsWidget .dealItemContent .dealItemdesc, #fiveDealsWidget .dealItemContent .dealItemRate {clear:both} }

This post first appeared on Dailymail.co.uk

You May Also Like

Electric cars: Ofgem plans easier way for drivers to sell energy back to grid

Proposal by Great Britain’s regulator is to help make the switch from…

Vodafone and Three in merger talks to become UK’s biggest telecoms provider

MOBILE network Three is in talks to merge with Vodafone to roll-out…

My broadband keeps cutting out – can I demand a discount from BT? Consumer rights lawyer Dean Dunham replies

In January I switched my broadband to BT, as I needed a…

Top tips to prepare for July’s household energy bills price drop

Household energy bills are set to drop from Saturday 1 July as…